*To the Editors*:

We read with interest the research letter by N[g]{.smallcaps} *et al.* \[[@C1]\], which described their experience in prone positioning (PP) for awake patients with coronavirus disease 2019 (COVID-19) pneumonia, and concluded that this manoeuvre could delay or reduce the need for intensive care. We agree that the authors demonstrated safety and feasibility of PP in COVID-19 pneumonia patients. However, we humbly suggest a few crucial points be addressed before drawing conclusions on the efficacy of PP.

First, the median time from illness onset to starting oxygen therapy (OT) and awake PP was 9 and 11 days, respectively. In a study reported by Y[oung]{.smallcaps} *et al.* \[[@C2]\], six out of 18 COVID-19 patients received OT as their oximetry saturations (*S*~pO~2~~) were \<92%, and median time from symptom onset to OT initiation was 4 days. Two among these six patients eventually needed intensive care for worsening respiratory failure. However, they had contrasting clinical trajectories, particularly in relation to tempo and extent of deterioration. The first patient desaturated at day 3, with rapid declining oxygenation that necessitated mechanical ventilation by day 8, while the second only developed hypoxia later at day 10 of illness. Although the latter was admitted to intensive care 3 days later, the patient needed at most venturi mask 50% and was successfully weaned by day 20 of illness. By referencing local data, it is plausible that most patients in the series reported by N[g]{.smallcaps} *et al.* \[[@C1]\] were at low risk of developing severe COVID-19 pneumonia prior to awake PP.

Second, there was considerable patient heterogeneity with regard to severity of hypoxaemia. Unreported information, *e.g.* chest radiology and protocol to guide PP management, limit data interpretation. COVID-19 pneumonia is increasingly recognised to manifest phenotypic diversity, rather than a strict dichotomy, *i.e.* phenotype L and H \[[@C3], [@C4]\]. Moreover, PP\'s physiological effects would only benefit phenotype H, *i.e.* typical acute respiratory distress syndrome (ARDS), as characterised by predominantly dorsal consolidation and poor respiratory compliance \[[@C4]\]. Studies on PP in non-intubated ARDS patients pre-dating COVID-19 reported oxygenation improvement but there was no demonstrable improvement in clinical outcomes \[[@C5]\]. There was, however, an increased risk of death attributed to delayed intubation in severe ARDS regardless of choice/combination of adjunct therapies, *e.g.* noninvasive ventilation/high flow nasal therapy (HFNT) \[[@C5], [@C6]\].

Third, all but one patient had *S*~pO~2~~ \>90% on room air at OT initiation. *S*~pO~2~~ ≥90% is an American Thoracis Society/Infectious Diseases Society of America 2007 criterion for clinical stability in hospitalised patients with community-acquired pneumonia \[[@C7]\]. Current guidelines do not recommend OT in acute myocardial infarction and stroke patients with *S*~pO~2~~ 90--92%, as evidence on its potential harm continues to emerge \[[@C8]\]. Similarly, we recommend judicious use of OT, as hyperoxia could exacerbate cytokine release syndrome -- the main immunopathological driver implicated in severe coronavirus infections \[[@C9]\]. It is regretful that the study of N[g]{.smallcaps} *et al.* \[[@C1]\] did not define indications for OT, which could explain the remarkably discrepant intubation rates (10% *versus* 60%) of COVID-19 pneumonia patients treated at the same centre.

Finally, we would like to share our experience on using awake PP and HFNT (PP+HFNT) in three patients since late April 2020 ([table 1](#TB1){ref-type="table"}). They were managed with the strategy below:1) Inclusion criteria*S*~pO~2~~ \<92% on intranasal oxygen ≥6 L·min^−1^ or venturi mask 50%; or PF ratio \<200Considerable bilateral opacities on chest radiograph, *i.e.* compatible with degree of hypoxaemiaRespiratory rate \<30 breaths·min^−1^Not using accessory muscles of respiration, *i.e.* sternocleidomastoidsNo contraindications to PP, *e.g.* cervical spine instability, pregnancy2) ManoeuvreFour 2-h sessions of PP daily3) Termination criteriaROX index persistently \<4.88 despite optimising HFNT and/or worsening clinical status requiring intubationPatient\'s inability to tolerate PPAll three patients required OT to keep *S*~pO~2~~ \>92% by one week of illness. Patients were at day 13, 16 and 8 of illness when PP+HFNT was started. The first two required 5 and 2 days of PP+HFNT while the last was intubated for worsening hypoxaemia after 4 days. Our observations echo those of Y[oung]{.smallcaps} *et al.* \[[@C2]\]. Just as the importance of personalised mechanical ventilation strategies cannot be overemphasised in COVID-19 ARDS, we maintain that selecting the appropriate patient subgroup for awake PP on OT is equally crucial. While we await more data, we opine that awake PP may work in hypoxic COVID-19 whereby the trajectory in oxygenation deterioration is less precipitous, meaning cytokine release syndrome is more indolent (thus causes ARDS over a longer time span), or already abating (the worst is over). Development of a prognostic model derived from clinical, laboratory and physiological data may predict risk of severe hypoxaemia requiring mechanical ventilation and guide personalised treatment in COVID-19 pneumonia.

###### 

Patient characteristics and parameters trends on PP+HFNT

  **Patient**                                                              **Patient 1**                        **Patient 2**      **Patient 3**                                                                           
  ------------------------------------------------------------------------ ------------------------------------ ------------------ ---------------- ------ ------ ------ -------- ------ ------ ----- ------ ------ ------ ------
  **Age and sex**                                                          55 years, male                       61 years, female   61 years, male                                                                          
  **Day of illness at OT initiation (*S*~pO~2~~** **\<92% on room air)**   7                                    5                  3                                                                                       
  **At PP+HFNT initiation**                                                Days of O~2~ received (cumulative)   7                  12               2                                                                      
  PF ratio                                                                 84.8                                 160                60.6                                                                                    
  **Time interval**                                                        Day of illness                       13                 14               15     16     17     18       16     17     18    8      9      10     11
  Day of PP                                                                1                                    2                  3                4      5      6      1        2      3      1     2      3      4      
  **Oxygen requirement**                                                   O~2~ devices                         HFNT               HFNT             HFNT   HFNT   HFNT   iNO~2~   HFNT   HFNT   VM    HFNT   HFNT   HFNT   HFNT
  *F*~IO~2~~ %                                                             100                                  40                 70               40     40            40       40     40     50    50     60     100    
  Flow L·min^−1^                                                           60                                   55                 60               50     50     4      55       55     12     50    60     70     70     
  **Respiratory parameters**                                               *S*~pO~2~~ %                         100                98               92     93     95     98       93     89     94    94     95     94     90
  PF ratio                                                                 114                                  170                77                      158           169             165    133   111    91     49     
  ROX index                                                                4.2                                  8.8                8.2              10.1   10.3   11.3   12.9     6.5    7.8    8.5   5.2    5.5    2.9    

PP: prone positioning; HFNT: high flow nasal therapy; OT: oxygen therapy; *S*~pO~2~~: peripheral oxygen saturation; iNO~2~: intranasal oxygen; VM: Venturi mask; *P*~aO~2~~: arterial oxygen tension; *F*~IO~2~~: inspiratory oxygen fraction; PF ratio: *P*~aO~2~~/*F*~IO~2~~ ratio; ROX index: ratio of *S*~pO~2~~/*F*~IO~2~~ to respiratory rate; Day of illness at OT initiation (*S*~pO~2~~ \<92% on room air): total days of symptoms onset before receiving supplemental oxygen (date of receiving supplemental oxygen -- date of symptoms onset + one day); Day of illness at PP+HFNT initiation: total days of illness before PP+HFNT (date of PP+HFNT initiated -- date of illness onset + one day); Days of O~2~ received at PP+HFNT initiation (cumulative): duration of patient on supplemental oxygen before PP+HFNT (date of PP+HFNT initiated -- date of receiving supplemental oxygen + one day).
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